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Lipid peroxidation (LPO) is a free radical-related process that in biologic systems may occur
under enzymatic control, e.g., for the generation of lipid-derived inflammatory mediators, or
nonenzymatically. This latter form is associated mostly with cellular damage as a result of
oxidative stress, which also involves cellular antioxidants in this process. This article focuses on
the relevance of two LPO products, malondialdehyde (MDA) and 4-hydroxynonenal (HNE), to the
pathophysiology of human disease. The former has been studied in human serum samples of
hepatitis C virus-infected adults and human immunodeficiency virus-infected children. In these
two cases it is shown that the specific assay of serum MDA is useful for the clinical
management of these patients. The presence of MDA in subretinal fluid of patients with retinal
detachment suggests the involvement of oxidative stress in this process. Moreover, we were
able to report the dependence of this involvement on the degree of myopia in these patients.
The assay of MDA contents in the peripheral nerves of rats fed a chronic alcohol-containing diet
or diabetic mice also confirms the pathophysiologic role of oxidative stress in these experimental
models. In these two cases, associated with an increase in tissue LPO products content, we
detected a decrease of glutathione peroxidase (GSHPx) activity in peripheral nerve, among other
modifications. We have demonstrated that in vitro HNE is able to inhibit GSHPx activity in an
apparent competitive manner, and that glutathione may partially protect and/or prevent this
inactivation. The accumulation of LPO products in the brain of patients with Alzheimer's disease
has also been described, and it is on the basis of this observation that we have tried to elucidate
the role of oxidative stress and cellular antioxidants in ,B-amyloid-induced apoptotic cell death of
rat embryo neurons. Finally, we discuss the possible role of the observed vascular effects of
HNE on human arteries. Environ Health Perspect 106(Suppl 5):1229-1234 (1998).
http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-5/1229-1234romero/abstract.html
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Introduction
Inflammation associated with infectious promote oxidative stress. Oxidative stress
and degenerative diseases, and probably was originally defined as the disequilibrium
others, leads to the activation of the so- between prooxidants and antioxidants in
called inflammatory cells. This activation biological systems (1). Once this imbalance
by means ofseveral mechanisms involving appears, cellular macromolecules may be
neutrophils, endothelial cells, etc., might damaged by the predominant free radicals.
This paper is based on a presentation at the Second International Meeting on Oxygen/Nitrogen Radicals and
Cellular Injury held 7-10 September 1997 in Durham, North Carolina. Manuscript received at EHP 19 December
1997; accepted 16 June 1998.
This work was partially supported by grants 96/1504 from Fondo de Investigaciones Sanitarias (Spain) and
PM96-0103 from Direccion General de Ensenahza (Spain) to FJR.
Address correspondence to F.J. Romero, Experimental Toxicology and Neurotoxicology Unit, Department of
Physiology, School of Medicine and Dentistry, University of Valencia, Avienda. Blasco lbanez, 17, 46010-
Valencia, Spain. Telephone: 34 6 386 4646. Fax: 34 6 386 4642. E-mail: fco.romero@uv.es
Abbreviations used: AD, Alzheimer's disease; ALT, alanine aminotransferase; CDC, Centers for Disease
Control and Prevention; CHC, chronic hepatitis C; GSH, glutathione; GSHPx, glutathione peroxidase; HCV,
hepatitis C virus; HIV, human immunodeficiency virus; HNE, 4-hydroxynonenal; IF, interferon a-2b; LPO, lipid
peroxidation; MDA, malondialdehyde; TBA, thiobarbituric acid; TBARS, thiobarbituric acid reactive substances.
This leads to oxidative modifications of
the genome, proteins, structural carbohy-
drates, and lipids; in the latter case, lipid
peroxidation (LPO) occurs. LPO is a free
radical-related process, that in biologic sys-
tems may occur under enzymatic control,
e.g., for the generation of lipid-derived
inflammatory mediators, or nonenzymati-
cally. This latter form is, as mentioned
above, associated mostly with cellular
damage as a result ofoxidative stress, and a
great variety ofaldehydes is formed when
lipid hydroperoxides break down in bio-
logical systems, among them, malondi-
aldehyde (MDA) and 4-hydroxynonenal
(HNE) (2).
To demonstrate involvement of
oxidative stress as pathophysiologic mech-
anisms in diseases or experimental models,
several approaches are possible. Because
oxidative stress may lead to cellular dam-
age, any marker ofcellular disruption may
confirm this role, although it may still be
necessary to demonstrate directly the
intervention ofoxidative stress. This may
be achieved by the direct detection ofacti-
vated species in situ, the assay of end
products of protein or lipid oxidation, or
any other oxidative modification of
macromolecules (modified bases of
nucleotides, etc.). Further evidence for the
role ofoxidative stress may be obtained by
studying the content and activity of
antioxidants. In this review, our data
attempt to demonstrate the crucial role of
oxidative stress in different disease and
experimental models. The goal is different
for each model. In some, the detection of
end products of LPO may help the clini-
cal management of these patients; in oth-
ers, oxidative stress participation is
reported for the first time. Finally other
results may help to understand patho-
physiologic mechanisms that are observed
in these diseases or experimental models.
We have studied serum MDA concen-
trations in two relevant viral infections that
have in common the involvement of T
cells: hepatitis C virus (HCV) in adults
(3), and pediatric human immuno-
deficiency virus (HIV) infections (4).
Moreover, we have demonstrated the
involvement of oxidative stress in retinal
detachment by detecting LPO products in
subretinal fluid of patients undergoing
surgery (5).
We have also demonstrated the patho-
physiologic role of oxidative stress in
experimental diabetic neuropathy (6) and
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chronic alcohol intoxication-induced
polyneuropathy (7). Interestingly, in these
two models LPO products accumulate in
peripheral nerve and both show a decrease
ofglutathione peroxidase (GSHPx) activity
in this same tissue. This finding led us to
investigate the effect ofHNE on this enzy-
matic activity in view of some recent
reports showing the ability of this com-
pound to inactivate other enzymes (8-11).
Because LPO products accumulate in the
brain ofpatients with Alzheimer's disease
(AD), we studied the role ofother cellular
antioxidants in in vitro models for the toxi-
city ofP-amyloid (the peptide accum-
ulating in the brain of AD patients)
(12,13), and in an experimental model of
spontaneous apoptosis (14). Finally, we
discuss the possible pathophysiologic role
of the reported effects of HNE on two
distinct vascular beds-human cerebral
(15) and mesenteric (16) arteries.
SemmMalondialdehyde inPatients
with Chronic Hepatitis C
It has been reported that serum LPO
products are increased in patients with
liver disease also in chronic hepatitis C
(CHC) patients (20).
The existence of an agent causing
non-A, non-B hepatitis was documented
by Alter et al. (21) and named hepatitis C
virus (HCV). Hepatitis C has some strik-
ing dinical features induding variability of
the serum activity ofalanine aminotrans-
ferase (ALT). In most cases this variability
does not correlate with the histopathologic
findings of the hepatic biopsies of these
patients (22) In addition, more than 50%
ofthe patients with acute hepatitis C will
develop chronic infection (23). Studies are
limited on HCV infection markers in
healthy-populations, as most use healthy
blood donors, but one could assume a vari-
able prevalence ranging from 0.26 to 2.3%
for anti-HCV in different parts of the
world (24-26). Thus, HCV infection is a
health problem worldwide. Moreover,
some ofthese liver diseases progress even-
tually to cirrhosis or even degenerates into
hepatocellular carcinoma (27,28). There
have been many attempts to find serologic
or cellular markers that may help in the
clinical management and evaluation of
treatment response of these patients,
including plasma viral load (29,30),
plasma anti-HCV IgM (31) or other solu-
ble immune factors (32), hepatic viral
RNA (33), etc. However, repeated biopsies
are needed to evaluate progression of the
disease (34).
We reported that serum LPO products
were significantly increased in a selected
group ofpatients with CHC before inter-
feron (IF) a-2 treatment (20). LPO prod-
ucts, measured as thiobarbituric acid
(TBA) reactive substances (TBARS) (20),
and also MDA (3) concentrations decreased
after IF-a2 treatment (3000 U, 3 times a
week for 6 months), as well as the ALT
activity, in serum ofthese patients. When
applying a specific assay ofMDA (fluores-
cence detection of the MDA-TBA after
chromatographic separation) (3,4), the dif-
ferences in serum MDA before and after
IF-a2 treatment, in the responding and
nonresponding IF-a2 treatment groups of
patients revealed that higher MDA values
before IF-aq treatment have a higher prob-
ability for a better outcome than those
with relatively lower values, as confirmed
histopathologically (3).
These results confirm involvement of
oxidative stress as part ofthe pathophysi-
ology of CHC. The increase in serum
MDA concentration in CHC patients may
fit in well with the recently reported GSH
depletion observed in hepatic tissue,
plasma, and peripheral blood mononuclear
cells of CHC patients (35). MDA values
apparently correspond with the severity of
the inflammatory findings whereas these
histopatholic signs do not correlate well
with the serum ALT activity (3). The fact
may be speculated as the predominant con-
tribution ofthe inflammatory cells over the
hepatocytes to the overall lipid peroxida-
tion rate. This speculation is reinforced by
the serum ALT activity levels (more
directly attributable to the hepatic cell
damage) that rapidly normalize during IF-
a2 treatment. Serum MDA levels, which
are significantly lower after IF-a2 treat-
ment, do not reach control values during
or after treatment (3). The possible role of
T cells in the development ofchronicity in
HCV-infected patients (23), acting proba-
bly as HCV reservoirs, has been recently
confirmed (36), and again it fits with the
above-mentioned lymphocytic glutathione
depletion observed in CHC patients (35).
Our results (3) should also be considered
for the clinical management of CHC
patients, as the effectiveness ofIF-a2 treat-
ment could be additionally tested by serial-
specific MDA determinations during the
course oftreatment.
SerumMalondialdeAyde in
PediatricHWInfection
Factors that correlate with the outcome of
the human immunodeficiency virus
(HIV) infection are needed for a better
understanding of the pathogenesis of this
infection and certainly for a better clinical
management of the infected individuals.
This is ofspecial relevance in particularly
important for HIV seropositive children.
HIV infection is associated with oxidative
stress., in view, among other things, ofthe
reduction ofglutathione GSH contents in
plasma and lung epithelial lining fluid
(37) and T lymphocytes (38) of adult
asymptomatic HIV seropositive individu-
als among other things. This decrease in
GSH is also associated with an increase in
the concentration of lipid peroxidation
products in serum of these patients (39).
Oxidative stress can occur early after the
HIV infection (40). Moreover, oxidative
stress might stimulate viral replication via
nuclear factor kappa B in T lymphocytes
(41), thus favoring the progression ofthe
disease. It has also been demonstrated that
some antioxidant substances might inhibit
this activation sequence in vitro. These
substances have been proposed as adjuvant
therapy in HIV infection (42,43).
The HIV infection in children has
some special features. Infants of HIV
seropositive mothers are almost always
seropositive at birth but might during the
first 18 months oflife turn seronegative if
they are not infected (44). Early treatment
ofthese children could improve life span.
We have recently demonstrated (4) that
HIV seropositive children have a higher
serum malondialdehyde concentration
than healthy children. In this preliminary
study we further demonstrated that total
antioxidant capacity of serum was dec-
reased in HIV seropositive children but not
always as significantly as serum MDA levels
increased, comparedwith the control group.
We have also developed a numerical model
to classify these children according to the
Centers for Disease Control and Prevention
(CDC) criteria in which we assume the
same distance between all clinical or
immunologic disease stages (N, A, B, and
C). We ascribed a numerical value to the
CDC classification criteria (N = 1, A= 2,
B =3, and C =4), thus transforming this
variable into a continuous one. Under these
conditions serum MDA levels correlated
with the different dinical categories in each
case. Interestingly, a high correlation was
observed between these two criteria in our
pediatric population (Spearman correlation
coefficient r=0.953) (45). We also showed
that an apparent negative correlation
(r= -0.515) could be established between
MDA values and CD4+ lymphocyte total
Environmental Health Perspectives * Vol 106, Supplement 5 * October 1998 1230LIPID PEROXIDATION AND ANTIOXIDANTS IN HUMAN DISEASE
count (46). These results are in agreement
with what is expected compared to the the
published results for adults, i.e., that CD4+
T cells were the best single predictor ofthe
progression to AIDS in HIV-infected
adults (47,48). These results provide the
basis for future studies that may prove this
hypothesis and may help in the clinical
management ofthese children.
LPO Product inTissues as
Oxidative Stress "Fingerprints"
LPO products and proteins accumulate in
the subretinal fluid ofpatients undergoing
retinal detachment surgery (5). The pres-
ence of MDA, and possibly other LPO
products, in human subretinal fluid raises
the questions ofwhere do these substances
come from and how does oxidative stress
intervene in the pathophysiology ofretinal
detachment. It is generally accepted that
retinal detachment is not normally associ-
ated with inflammation (49), a process
where free radicals and lipid-derived inter-
mediates play an important role (50,51).
However, Hackett et al. (52) have shown
that subretinal fluid stimulates in vitro
migration and proliferation of retinal pig-
ment epithelial cells, and Goto et al. (53)
found that retinal structural membrane
peroxidized lipids have chemotactic prop-
erties. Moreover, the presence of LPO
products in the vicinity of the retina, e.g.,
in the subretinal fluid, might have vascular
consequences (discussed below). This has
been preliminarily demonstrated by the
intravitreal injection into the rabbit eye of
relatively low concentrations of HNE,
showing an intense inflammatory response
with impairment ofthe blood-retina bar-
rier (54,55). The cellular elements most
likely responsible for the initial generation
of the necessary free radicals to induce
LPO, or for the initial reaction to the
presence ofalready generated free radicals,
are retinal pigment epithelial cells, phago-
cytic cells that generate superoxide anion
during phagocytosis ofrod outer segments
(56). The presence in the human retina
of a relevant GSH content and GSH-
associated conjugating activity towards
HNE (57) may certainly play a role in the
ultimate defense against oxidative damage
and LPO, one of its direct consequences.
The fact that hyaluronic acid depolymer-
ization, associated with vitreous liquefac-
tion, appears during rhegmatogenous
retinal detachment (49), and that this
depolymerization is induced by oxygen
free radicals (58,59), again fits in the
previous hypothesis.
This same approach, i.e., the evaluation
oftissue LPO products levels in tissues, has
been also applied to experimental models
with similar results. We have focused in the
last few years on the role ofoxidative stress
in peripheral nervous tissue affections, i.e.,
neuropathies. This has been reviewed else-
where (60). Relevant to the present mono-
graph, however, is the fact that associated
with the accumulation ofLPO products in
peripheral nervous tissue in models ofexper-
imental diabetes (61) or chronic alcoholic
intoxication (7), a decrease in GSHPx activ-
ity occurs in this same tissue (6,7,62,63),
among other cellular antioxidants (64,65).
4-Hydroxynonenal Inhibits GSHPx
The alterations observed in GSHPx activity
might be related to different mechanisms.
However, the reported ability of HNE to
modify proteins and therefore influence
enzymatic activity, led us to study the pos-
sibility of a direct interaction between
HNE and GSHPx. HNE reacts with GSH
spontaneously, but within cells this reac-
tion proceeds at a much higher rate, cat-
alyzed by specific isoforms of GSH
S-transferases (66,67). Moreover, reaction
of this aldehyde with other aminoacid
residues leads to the modification of pro-
teins and eventually to the inactivation of
their enzymatic activity. It has been
demonstrated the modification ofhistidine
residues in insulin (8) after incubation
with HNE (8), as well as the inactivation
ofglucose 6-phosphate dehydrogenase by
the HNE-induced selective modification of
an active-site lysine residue (9), the inhibi-
tion ofNa,K-ATPase most probably by the
interaction of the HNE with sulfhydryl
groups (11), etc.
Incubation of GSHPx with HNE
resulted in a loss ofenzymatic activity, in a
time-and concentration-dependent fash-
ion. Over 90% of the inhibition observed
for each ofthe different concentrations was
achieved in the first 30 min, and no further
loss ofactivity could be detected. We cal-
culated the concentration that exerted 50%
inactivation of the enzyme (150) as 0.12
mM. We tested whether the substrates
would be able to protect the enzyme, and
found that 1 mM GSH added 30 min
prior to the addition of the aldehydes pre-
vented GSHPx from inactivation almost
completely. Furthermore, GSH reverted,
the initial inactivation, at least partially,
even when GSH was added after incuba-
tion with HNE. From the results ofkinetic
studies, it can be deduced that HNE is
apparently able to competitively inhibit
GSHPx (68). The 15o value for HNE
inhibition is in the range of those previ-
ously reported for several enzymes (69),
and interestingly, coincides with the I50
value obtained for Na,K-ATPase (11).
These authors proposed the contribution
of cysteine residues in the inhibition of
Na,K-ATPase according to the protection
exerted by thiol reagents. GSHPx inhibi-
tion seems to be competitive. This is
apparently in contrast with the results of
the HNE-induced glucose 6-phosphate
dehydrogenase inactivation, where a dou-
ble reciprocal plot evidenced a noncom-
petitive mode of action for the inhibition
exerted by glucose 6-phosphate on HNE-
induced inactivation (9). In considering
the data on GSH protection and the
kinetic studies referred to above, it seems
also more than reasonable that one or
more amino acid residues not far from the
active site might be modified. The most
plausible candidate could be Lys or His,
according to the proposed reactivity of
these residues with HNE (8,9).
Pathophysiologic Relationship of
LipidPeroxidation Products and
Antioxidants
Oxygen radicals and lipid peroxidation
play a pivotal role in the observed damage
during central nervous system trauma and
stroke (70) (71), and more generally in
neurotoxicity (72). Both oxygen radicals
and peroxides are able to inactivate antioxi-
dant enzymes (73). The role of GSH and
GSH-related enzymes in the defense of
neurons against oxidative burden has been
repeatedly suggested (60,74,75). It has
been recently reported that HNE has a role
in ,-amyloid-induced neuronal death
(76), whereas it is also known that 3-amy-
loid-induced apoptosis is associated with
GSH depletion in primary neurons
(12,13). The hypothesis of the involve-
ment ofoxidative stress in AD (77) is con-
firmed also by the finding ofincreased lipid
peroxidation products levels in brains of
these patients (78).
As mentioned above, HNE is able to
impair Na,K-ATPase activity (11), and it
has been proposed that HNE would medi-
ate j-amyloid-induced oxidative damage
to neuronal membrane proteins (76). As
it has been recently demonstrated that ,-
amyloid-induced apoptosis is associated
with GSH depletion in neurons (12,13),
collectively, all these data demonstrate the
pathophysiologic relevance of these find-
ings. An additional HNE-induced inhibi-
tion ofGSH-Px in neurons that are already
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challenged by f3-amyloid may certainly
close the vicious circle leading to cell death.
Furthermore, it provides a rationale for
considering selenoorganic compounds with
GSHPx-like activity, such as ebselen
(79,80), for the treatment ofAD and
probably other neurodegenerative diseases.
Another open field is related to the mecha-
nisms involved in this cell death process
and its different forms, as antioxidants cer-
tainly are involved in cell death ofdifferent
cell types in certain diseases mentioned in
this monograph (HIV infection, AD, etc).
The involvement ofoxygen free radicals
and cellular antioxidants such as GSH in
the apoptotic process seems to be accepted
by the majority ofinvestigators. However,
the sequence of intervention ofthese ele-
ments in the different models proposed up
to now is still an open question. In this
sense, we have recently reported the varia-
tions ofcellular GSH levels in a model of
spontaneous apoptosis-V79 multicellular
spheroids (14).
VascularEffectsofHydoxynonenal
LPO products such as lipid hydroperoxides
(81) and aldehydes (15,82) show vascular
effects in a variety of territories. Unlike
reactive free radicals, aldehydes are rather
long-lived and can therefore spread from
their site of origin and attack targets
distant from the initial radical event (2) by
circulating in blood. The action of HNE
in endothelial cells has been studied in cul-
ture in terms ofits cytotoxicity (83) and,
in human cerebral arteries, from a func-
tional point ofview (15). The reported
physiologic human plasma levels of HNE
range from 0.3 to 0.7 pM (84,85), and it
has been demonstrated that levels increase
in experimental alcoholic liver disease
(86), An increase in circulating LPO
products (determined as the TBARS), as it
is observed in different human hepatic dis-
eases (18) including hepatitis C (3,20) as
mentioned above, would conceivably
include a specific increase in circulating 4-
HNE. We recently reported the relaxing
effect ofHNE on human mesenteric arter-
ial segments, and its possible implications
in the hemodynamic alterations observed
during hepatic cirrhosis (16). These
results confirm that the HNE relaxing
effect is mostly mediated by the endothe-
lium, as was previously reported in human
cerebral arteries (15). HNE concentration
in human biologic fluids has not been sys-
tematically studied in the disease state due
to the difficulty of the procedures
described up to now (2,87). However,
some evidence confirms that this aldehyde
is increased in situations where other alde-
hydic LPO products are increased (88),
and vice versa (89). The most frequent
causes of portal hypertension and ascitis
are liver diseases such as alcoholic hepati-
tis, cirrhosis, and cancer, etc. LPO is
enhanced during all phases of human
hepatic alcoholic disease, as can be
inferred by the serum MDA increase dur-
ing viral hepatitis (19,20), experimental
hepatic alcoholic disease (86), etc. If the
increase of LPO products concentration
in serum supposes also an increase in
HNE, the results mentioned above (16)
would at least partially explain the hemo-
dynamic alterations observed during por-
tal hypertension. The increase in
hydrostatic pressure does not completely
explain the intense splanchnic arteriolar
vasodilation responsible for the increase in
cardiac output, arterial hypotension,
hypervolemia, and decreased peripheral
resistence found in these patients. The
results presented support the proposal of
HNE as one of the possible metabolites
that contribute to these alterations.
Further systematic studies are being
undertaken to prove this hypothesis.
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